Previous 10 | Next 10 |
2023-12-09 07:00:00 ET Sarepta Therapeutics (NASDAQ: SRPT) is a mid-cap stock that has the potential to be a big player in the gene therapy market -- at least, so the business and its investors hope. It has made for a volatile investment in recent years, but with a possible game-cha...
2023-12-08 05:25:00 ET Are you looking for new growth stocks for your portfolio? The idea was compelling a week ago when the market was roaring higher. Now, with fresh headwinds blowing, not so much. Just bear in mind there are some growth stories that are too good to ignore, just as th...
2023-12-04 16:00:53 ET More on Sarepta Therapeutics Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clinical Data Concerns Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Call Transcript Sarepta Therapeutics, Inc. 2023 Q3 - Results - Earnings Call P...
2023-12-01 11:17:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-18 06:49:00 ET Most, if not all, of the market's current mega-cap stocks started out much smaller. Investors who spotted their potential early had opportunities to make fortunes over time. Which smaller stocks today could be monsters in the making? Here's why three Motley Fool c...
2023-11-15 06:45:38 ET Summary Solid Biosciences receives FDA clearance for clinical testing of DMD gene therapy. Chevron is reviewing options for its Texas Haynesville shale assets, including a potential sale. U.S. House passes spending bill to avoid government shutdown, Sena...
2023-11-14 17:05:16 ET More on Solid Biosciences Solid Biosciences reports Q3 results Solid Bio draws new Overweight rating at Cantor on valuation Seeking Alpha’s Quant Rating on Solid Biosciences Historical earnings data for Solid Biosciences ...
2023-11-11 01:09:05 ET Summary Sarepta Therapeutics reported strong earnings and revenue figures, with a 49% increase in net product revenues. The company's newest therapy, ELEVIDYS, generated $69.1M in net product revenues in its first quarter on the market. Although ELEVIDYS...
2023-11-09 10:00:00 ET Investing in biotech stocks is risky. And one of the more volatile ones of late is Sarepta Therapeutics (NASDAQ: SRPT) . Shares of the company crashed last week after it released results from phase 3 trials, which failed to impress investors and analysts. Is t...
2023-11-08 10:15:00 ET Biotech companies working on gene therapies have made significant strides lately, but many of them remain relatively risky stocks. Still, gene therapies have the potential to help transform medicine by unlocking treatments or cures for illnesses that have so far elude...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...